Pardoll 2012: the blockade of immune checkpoints in cancer immunotherapy
The review that named and organised the field of checkpoint blockade: tumours switch off attacking T cells through brakes such as CTLA-4 and PD-1, and antibodies that release those brakes can produce lasting responses.
Overview
Written as the first PD-1 antibody results appeared, Pardoll's review explained how immune checkpoints, receptors that normally protect tissues from autoimmunity, are exploited by tumours, and why blocking them is a fundamentally different approach from vaccines or cytokines. It contrasted CTLA-4, which acts early in lymph nodes, with PD-1 and its ligand PD-L1, which act in the tumour itself, catalogued further checkpoints such as LAG-3 and TIM-3, and set out the questions that have shaped the decade since: biomarkers, combinations, and the autoimmune side effects that come with releasing the brakes.
- Immune checkpoints are inhibitory receptors on T cells that tumours co-opt; CTLA-4 acts mainly during T cell priming and PD-1 during the effector phase in tissues.
- PD-L1 expression by tumour cells offers a mechanism-based biomarker and a rationale for anti-PD-1 and anti-PD-L1 antibodies.
- Multiple additional checkpoints (LAG-3, TIM-3, BTLA, adenosine and others) offer combination targets.
This is the most cited map of the immunotherapy revolution and a good first read before the trials. Its predictions largely held: PD-1 pathway antibodies became the most widely used cancer drugs, PD-L1 testing entered practice, and LAG-3 blockade was approved in melanoma a decade later.
- A review written before most phase 3 evidence existed.
- Biomarkers for checkpoint blockade remain imperfect despite the mechanistic case for PD-L1.
This paper turned a hypothesis into a biomarker: tumour mutational burden is now measured by commercial panels and underpins the tissue-agnostic approval of pembrolizumab for TMB-high tumours. It also explains why smokers' lung cancers, long the hardest to treat, respond better to immunotherapy than never-smokers' cancers.
Immunoediting is the conceptual backbone of modern immuno-oncology: it explains tumour heterogeneity, dormancy and late relapse, and why immunotherapy works by releasing pre-existing but suppressed immunity.
Similar pages
not linked directly; found by shared links- TargetVISTA
- Key paperTumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge
Shares Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer, Immune checkpoint, PD-L1, PD-1.
- PersonGordon J. Freeman
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, PD-L1, PD-1, Immune checkpoint inhibitors.
- PersonF. Stephen Hodi
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, CTLA-4, PD-1.
- PersonLieping Chen
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, PD-L1, PD-1, Immune checkpoint inhibitors.
- TermHallmark: avoiding immune destruction
Shares LAG-3, Immune checkpoint, CTLA-4, PD-L1.
- PersonPadmanee Sharma
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CTLA-4, PD-1, Immune checkpoint inhibitors.
- Key paperCheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, LAG-3, Immune-related adverse events (irAEs), CTLA-4.